Advaxis Stock Price

0.0062 (1.32%)


52 Week Range


Best deals to access real time data!
Ultimate Trader (Monthly)
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Big Cap Pro
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Advaxis Inc ADXS NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.0062 1.32% 0.4752 08:07:27
Open Price Low Price High Price Close Price Prev Close
Bid Price Ask Price Spread News
0.473 0.475 0.002 - -
Trades Volume Avg Volume 52 Week Range
130 61,300 14,330,201 0.2645 - 1.57
Last Trade Time Type Quantity Stock Price Currency
08:07:27 92 $ 0.4752 USD

Advaxis Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 52.19M 109.82M 109.76M $ 20.88M $ - 0.02 -1.50
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Advaxis News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical ADXS Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.650.65490.4620.53723486,712,324-0.1748-26.89%
1 Month0.86770.870.4620.65408874,005,058-0.3925-45.23%
3 Months0.76651.570.4620.93196919,815,863-0.2913-38.0%
6 Months0.41181.570.26450.69840579,749,8540.063415.4%
1 Year0.641.570.26450.68353895,391,824-0.1648-25.75%
3 Years1.7310.800.1810.73743373,567,267-1.25-72.53%
5 Years9.7916.2950.1811.552,466,545-9.31-95.15%

Advaxis Description

Advaxis Inc is a clinical stage biotechnology company operating in the United States. It focuses on discovery, development, and commercialization of proprietary Lm (Listeria monocytogenes)-LLO (Listeriolysin O) cancer immunotherapies. These immunotherapies are based on a platform technology which utilizes live attenuated Listeria monocytogenes (Lm) bioengineered to secrete antigen/adjuvant fusion proteins. The company's immunotherapy products based on Lm-LLO immunotherapy are Axalimogene filolisbac (AXAL) which targets Human Papilloma Virus (HPV) - associated cancers and ADXS-PSA which targets Prostate Specific Antigen (PSA) associated with prostate cancer.

Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.